Molecular Diagnosis & Therapy

, Volume 10, Issue 2, pp 67–76 | Cite as

Anticipating Clinical Resistance to Target-Directed Agents

The BCR-ABL Paradigm
Cancer

Abstract

The deregulated tyrosine kinase activity of BCR-ABL is necessary and sufficient to induce chronic myelogenous leukemia (CML). This observation has paved the way for the development of small-molecule inhibitors specifically targeting the kinase activity of the BCR-ABL protein. Indeed, the amazing success of imatinib has revolutionized the whole area of targeted cancer therapeutics. However, enthusiasm for the striking efficacy of imatinib has been tempered by the development of clinical resistance. In essentially all cases, resistance results from kinase domain mutations and/or overexpression of the BCR-ABL gene. To overcome resistance, several novel BCR-ABL inhibitors have been developed and are in clinical trials, though it is inevitable that resistance to second-generation inhibitors will occur as well. Nonetheless, kinases represent an attractive target for therapeutic intervention in several diseases and, at present, some 50 different kinase inhibitors are in clinical trials. We anticipate that resistance to these compounds will follow mechanisms similar to those observed with imatinib. Resistance mutations cause their effect either by direct steric hindrance to drug binding or by allosterically modulating kinase dynamics. This review highlights the principal mechanisms underlying point mutations from these two different classes to confer drug resistance.

Notes

Acknowledgments

The authors wish to thank members of the Daley lab for critical review and revision of the manuscript, especially Drs Shannon M. Freeman, William M. Lensch, and Frank Yates.

Research was supported by grants from the National Institutes of Health (NIH), the NIH Director’s Pioneer Award of the NIH Roadmap for Medical Research, and by the Thomas Anthony Pappas Charitable Foundation. GQD is a recipient of the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.

The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57–70PubMedCrossRefGoogle Scholar
  2. 2.
    Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411(6835): 355–65PubMedCrossRefGoogle Scholar
  3. 3.
    Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109(3): 275–82PubMedCrossRefGoogle Scholar
  4. 4.
    Melnikova I, Golden J. Targeting protein kinases. Nat Rev Drug Discov 2004; 3(12): 993–4PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1(4): 309–15PubMedCrossRefGoogle Scholar
  6. 6.
    Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2(4): 296–313PubMedCrossRefGoogle Scholar
  7. 7.
    Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303(5665): 1800–5PubMedCrossRefGoogle Scholar
  8. 8.
    Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340(17): 1330–40PubMedCrossRefGoogle Scholar
  9. 9.
    Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science 1960; 132: 1497Google Scholar
  10. 10.
    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973; 243(5405): 290–3PubMedCrossRefGoogle Scholar
  11. 11.
    Kelliher MA, McLaughlin J, Witte ON, et al. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad sci USA 1990; 87(17): 6649–53PubMedCrossRefGoogle Scholar
  12. 12.
    Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003; 349(15): 1451–64PubMedCrossRefGoogle Scholar
  13. 13.
    Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96(10): 3343–56PubMedGoogle Scholar
  14. 14.
    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105(7): 2640–53PubMedCrossRefGoogle Scholar
  15. 15.
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247(4944): 824–30PubMedCrossRefGoogle Scholar
  16. 16.
    Daley GQ, Van Etten RA, Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad sci U S A 1991; 88(24): 11335–8PubMedCrossRefGoogle Scholar
  17. 17.
    Kantarjian HM, O’Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97(4): 1033–41PubMedCrossRefGoogle Scholar
  18. 18.
    Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 2005 Aug; 84(8): 487–97PubMedCrossRefGoogle Scholar
  19. 19.
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5): 561–6PubMedCrossRefGoogle Scholar
  20. 20.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031–7PubMedCrossRefGoogle Scholar
  21. 21.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038–42PubMedCrossRefGoogle Scholar
  22. 22.
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645–52PubMedCrossRefGoogle Scholar
  23. 23.
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928–37PubMedCrossRefGoogle Scholar
  24. 24.
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530–9PubMedCrossRefGoogle Scholar
  25. 25.
    Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96(3): 1070–9PubMedGoogle Scholar
  26. 26.
    le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95(5): 1758–66PubMedGoogle Scholar
  27. 27.
    Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95(11): 3498–505PubMedGoogle Scholar
  28. 28.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531): 876–80PubMedCrossRefGoogle Scholar
  29. 29.
    Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2(2): 117–25PubMedCrossRefGoogle Scholar
  30. 30.
    Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22(47): 7389–95PubMedCrossRefGoogle Scholar
  31. 31.
    Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9(4): 303–7PubMedCrossRefGoogle Scholar
  32. 32.
    Donate NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101(2): 690–8CrossRefGoogle Scholar
  33. 33.
    Dai Y, Rahmani M, Corey SJ, et al. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279(33): 34227–39PubMedCrossRefGoogle Scholar
  34. 34.
    Donate NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64(2): 672–7CrossRefGoogle Scholar
  35. 35.
    Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18(8): 1321–31PubMedCrossRefGoogle Scholar
  36. 36.
    Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11(1): 35–43PubMedCrossRefGoogle Scholar
  37. 37.
    Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999; 9(5): 179–86PubMedCrossRefGoogle Scholar
  38. 38.
    Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5(1): 33–44PubMedCrossRefGoogle Scholar
  39. 39.
    Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112(6): 831–43PubMedCrossRefGoogle Scholar
  40. 40.
    Harrison SC. Variation on an Src-like theme. Cell 2003; 112(6): 737–40PubMedCrossRefGoogle Scholar
  41. 41.
    Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003; 112(6): 859–71PubMedCrossRefGoogle Scholar
  42. 42.
    Hantschel O, Nagar B, Guettler S, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003; 112(6): 845–57PubMedCrossRefGoogle Scholar
  43. 43.
    Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289(5486): 1938–42PubMedCrossRefGoogle Scholar
  44. 44.
    Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62(15): 4236–43PubMedGoogle Scholar
  45. 45.
    Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293(5538): 2163PubMedCrossRefGoogle Scholar
  46. 46.
    Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100(3): 1014–8PubMedCrossRefGoogle Scholar
  47. 47.
    Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003; 40(2 Suppl. 2): 80–2PubMedCrossRefGoogle Scholar
  48. 48.
    Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad sci U S A 2002; 99(16): 10700–5PubMedCrossRefGoogle Scholar
  49. 49.
    Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99(9): 3472–5PubMedCrossRefGoogle Scholar
  50. 50.
    Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102(1): 276–83PubMedCrossRefGoogle Scholar
  51. 51.
    Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105(5): 2093–8PubMedCrossRefGoogle Scholar
  52. 52.
    Corbin AS, La Rosee P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101(11): 4611–4PubMedCrossRefGoogle Scholar
  53. 53.
    Piazza RG, Magistroni V, Gasser M, et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia 2005; 19(1): 132–4PubMedGoogle Scholar
  54. 54.
    Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23(18): 4100–9PubMedCrossRefGoogle Scholar
  55. 55.
    Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104(9): 2926–32PubMedCrossRefGoogle Scholar
  56. 56.
    Barthe C, Cony-Makhoul P, Melo JV, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293(5538): 2163PubMedCrossRefGoogle Scholar
  57. 57.
    von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359(9305): 487–91CrossRefGoogle Scholar
  58. 58.
    Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3(12): 1001–10PubMedCrossRefGoogle Scholar
  59. 59.
    Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5(1): 55–60PubMedCrossRefGoogle Scholar
  60. 60.
    Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106(6): 2128–37PubMedCrossRefGoogle Scholar
  61. 61.
    Azam M, Raz T, Nardi V, et al. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online 2003; 5: 204–10PubMedCrossRefGoogle Scholar
  62. 62.
    Martinelli G, Soverini S, Rosti G, et al. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005; 90(4): 534–41PubMedGoogle Scholar
  63. 63.
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497–500PubMedCrossRefGoogle Scholar
  64. 64.
    Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305(5687): 1163–7PubMedCrossRefGoogle Scholar
  65. 65.
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129–39PubMedCrossRefGoogle Scholar
  66. 66.
    Liu Y, Shah K, Yang F, et al. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg Med Chem 1998; 6(8): 1219–26PubMedCrossRefGoogle Scholar
  67. 67.
    Bishop AC. A hot spot for protein kinase inhibitor sensitivity. Chem Biol 2004; 11(5): 587–9PubMedCrossRefGoogle Scholar
  68. 68.
    Nolen B, Taylor S, Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 2004; 15(5): 661–75PubMedCrossRefGoogle Scholar
  69. 69.
    Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127(1): 294–9PubMedCrossRefGoogle Scholar
  70. 70.
    Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348(13): 1201–14PubMedCrossRefGoogle Scholar
  71. 71.
    Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad sci U S A 2005; 102(21): 7665–70PubMedCrossRefGoogle Scholar
  72. 72.
    Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352(8): 786–92PubMedCrossRefGoogle Scholar
  73. 73.
    Wakai T, Kanda T, Hirota S, et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004; 90(11): 2059–61PubMedGoogle Scholar
  74. 74.
    Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99(5): 1741–4PubMedCrossRefGoogle Scholar
  75. 75.
    Dorsey JF, Jove R, Kraker AJ, et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000; 60(12): 3127–31PubMedGoogle Scholar
  76. 76.
    Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002; 62(15): 4244–55PubMedGoogle Scholar
  77. 77.
    von Bubnoff N, Veach DR, Miller WT, et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003; 63(19): 6395–404Google Scholar
  78. 78.
    Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305(5682): 399–401PubMedCrossRefGoogle Scholar
  79. 79.
    Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7(2): 129–41PubMedCrossRefGoogle Scholar
  80. 80.
    Burgess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad sci U S A 2005; 102(9): 3395–400PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of Biological Chemistry and Molecular PharmacologyHarvard Medical SchoolBostonUSA

Personalised recommendations